SK Life Science, Inc.
$5.1M 20,538 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. reported $5,133,141.31 across General Payments, Research, and Ownership to 13,236 physicians and teaching hospitals across 13,623 transactions.
- $5.1M
- All-tracks total
- 13,623
- Transactions
- 13,236
- Recipients
- −$1.4M
- General Payments vs PY2023
Intercept Pharmaceuticals, Inc. reported $5,133,141.31 across all CMS Open Payments tracks (General + Research + Ownership) to 13,236 physicians and teaching hospitals in Program Year 2024 - ranking #269 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,765,551.26, averaging $387.82 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer intercept-pharmaceuticals-inc Intercept Pharmaceuticals, Inc.
$5.1M · #269/1,925 · 0.0% industry · PY2024
- TOT $5.1M
- RANK #269
- SHARE 0.0%
- TXN 13,623
- RCP 13,236
- CAT 7
- GEN $2.8M
- ΔGEN −$1.4M
- TOP1 31.9%
- PY 2024
Volume peers
Nearest volume peer: SK Life Science, Inc. ($5.1M)
Intercept Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Intercept Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $1.4M (−33.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INTERCEPT PHARMACEUTICALS, INC.PY2023: INTERCEPT PHARMACEUTICALS, INC.PY2024: Intercept Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $4,182,258.34
- PY2024
- $2,765,551.26
What the Data Shows for Intercept Pharmaceuticals, Inc.
Rank #269 of 1,925 companies in CMS Open Payments for 2024 belongs to Intercept Pharmaceuticals, Inc., which reported $5,133,141.31 across 13,623 transactions to 13,236 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $376.80 per transaction and $387.82 per recipient.
"Consulting Fee" leads the 7-category general-payment breakdown below at $1.5M (55.4% of General Payments, 113 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 7 types of general payments, Intercept Pharmaceuticals, Inc.'s largest category was "Consulting Fee" at $1.5M - 55.4% of General Payments.
Intercept Pharmaceuticals, Inc. reports 7 general-payment categories - the top three are Consulting Fee (55.4%), Compensation for Faculty or Speaker (Medical Education) (26.6%), and Food and Beverage (10.8%). The remaining 4 categories make up 7.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Intercept Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.5M | 113 | 55.4% |
| Compensation for Faculty or Speaker (Medical Education) | $736.6K | 267 | 26.6% |
| Food and Beverage | $298.2K | 12,596 | 10.8% |
| Honoraria | $98.5K | 65 | 3.6% |
| Travel and Lodging | $76.4K | 152 | 2.8% |
| Space Rental or Facility Fees | $23.5K | 9 | 0.8% |
| Education | $415.34 | 34 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,379,968.00 (49.9%) of $2,765,551.26 in this company's General Payments records across 6,512 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Intercept Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Haytham Elgammal
$883,348.88 across 16 reported transactions
- 2
University Of Iowa Hosp & Clinics
$212,853.17 across 27 reported transactions
- 3
Robert Gish
$134,404.04 across 53 reported transactions
- 4
Robert Brown
$76,795.91 across 10 reported transactions
- 5
Nezam Afdhal
$72,566.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Intercept Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Intercept Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Intercept Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Pristine Surgical LLC
$5.1M 5 recipients
Compare payment profiles
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
Actelion Pharmaceuticals US, Inc.
$5.2M 31,311 recipients
Compare payment profiles
ADC Therapeutics America, Inc.
$5.1M 4,269 recipients
Compare payment profiles
Jcbd, LLC
$5.1M 10 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.